Radiopharm Theranostics Ltd (RADX) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including promising Phase 2b clinical trial results and analyst upgrades with increased price targets. While technical indicators are neutral, the long-term growth potential and market opportunity in brain metastasis diagnostics make it a compelling investment.

Technical Analysis

The MACD is positive and contracting, indicating mild bullish momentum. RSI is neutral at 48.222, suggesting no overbought or oversold conditions. Moving averages are converging, reflecting a lack of a clear trend. Key support is at 4.748, and resistance is at 5.396.

Positive Catalysts

Positive interim Phase 2b clinical trial results for RAD101, with 92% MRI concordance.
Analysts have raised price targets significantly, citing strong trial data and a $500M market opportunity in brain metastasis diagnostics.
New clinical trial for 177Lu-BetaBart targeting advanced solid tumors, indicating a robust pipeline.

Neutral/Negative Catalysts

Lack of significant insider or hedge fund trading trends.
No recent congress trading data available.
Neutral technical indicators suggest no immediate momentum.

Financial Performance

Financial data is unavailable for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are bullish, with Maxim raising the price target to $15 and B. Riley raising it to $16, both maintaining Buy ratings. Analysts cite strong clinical trial results and significant market potential as key drivers.

3 Analyst Rating

Wall Street analysts forecast RADX stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 4.990

Low

Averages

20.33

High

Current: 4.990

Low

Averages

20.33

High

Maxim

Michael Okunewitch

NULL -> Buy

upgrade

$12 -> $15

AI Analysis

2025-12-17

Reason

Maxim

Michael Okunewitch

Price Target

$12 -> $15

AI Analysis

2025-12-17

upgrade

NULL -> Buy

Reason

Maxim analyst Michael Okunewitch raised the firm's price target on Radiopharm to $15 from $12 and keeps a Buy rating on the shares. The firm cites the company having announced positive results on its primary endpoint in an interim analysis of the first 12 patients in the Phase 2b study of RAD 101, as the study demonstrated concordance with MRI in 92% of patients treated with RAD 101 as a PET imaging agent for brain metastases, the analyst tells investors in a research note. The initial data emerging from the Phase 2b study of RAD 101 in brain metastasis imaging is highly encouraging and de-risks Radopharm's potential to address the $500M market opportunity in brain mets diagnostics and monitoring, the firm added.

B. Riley

Buy

maintain

$13 -> $16

2025-12-16

Reason

B. Riley

Price Target

$13 -> $16

2025-12-16

maintain

Buy

Reason

B. Riley raised the firm's price target on Radiopharm to $16 from $13 and keeps a Buy rating on the shares. Radiopharm reported positive interim Phase 2b imaging data for RAD101 in brain metastases, with 92% MRI concordance and clear, selective tumor uptake consistent with prior Phase 2a results, the analyst tells investors in a research note. Enrollment is over 50% in the 30-patient study, with final data expected in the first half of 2026 to inform Phase 3 design ahead of a planned FDA meeting in mid-2026, B. Riley adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RADX

Unlock Now

RADX Should I Buy

RADX Should I Buy

Should You Buy Radiopharm Theranostics Ltd (RADX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch